Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) was the target of a significant drop in short interest in June. As of June 15th, there was short interest totalling 92,000 shares, a drop of 58.8% from the May 31st total of 223,200 shares. Based on an average daily trading volume, of 1,476,400 shares, the days-to-cover ratio is currently 0.1 days.
Wall Street Analysts Forecast Growth
BAYRY has been the subject of several analyst reports. Citigroup reissued a “neutral” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, February 29th. The Goldman Sachs Group initiated coverage on shares of Bayer Aktiengesellschaft in a research note on Thursday, May 30th. They issued a “neutral” rating for the company. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Bayer Aktiengesellschaft in a research note on Thursday, March 7th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold”.
View Our Latest Stock Analysis on Bayer Aktiengesellschaft
Bayer Aktiengesellschaft Trading Up 0.3 %
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last announced its quarterly earnings results on Tuesday, May 14th. The company reported $0.77 earnings per share (EPS) for the quarter. Bayer Aktiengesellschaft had a positive return on equity of 17.57% and a negative net margin of 6.70%. The business had revenue of $14.95 billion during the quarter. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.36 earnings per share for the current year.
Bayer Aktiengesellschaft Cuts Dividend
The company also recently announced a dividend, which was paid on Monday, May 13th. Stockholders of record on Tuesday, April 30th were issued a dividend of $0.0191 per share. The ex-dividend date was Monday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio is currently -2.30%.
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
See Also
- Five stocks we like better than Bayer Aktiengesellschaft
- What is the Dogs of the Dow Strategy? Overview and Examples
- Albemarle Stock: Strong Fundamentals vs. Lithium Volatility
- Dividend Capture Strategy: What You Need to Know
- MongoDB Stock: Analysts Recommend Buying the Dip
- Stock Sentiment Analysis: How it Works
- UniFirst Stock: Value-Building Sends a Signal to the Market
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.